CAPRICOR THERAPEUTICS, INC.

Form 8-K July 28, 2014	
UNITED STATES	
SECURITIES AND EXCHANGE COMMISSIO	N
Washington, D.C. 20549	
FORM 8-K	
CVIDDENT DEPORT	
CURRENT REPORT	
Pursuant to Section 13 or 15(d) of	
The Securities Exchange Act of 1934	
Date of Report (Date of earliest event reported)	
July 16, 2014	
CAPRICOR THERAPEUTICS, INC.	
(Exact name of Registrant as Specified in its Cha	rter)
	663465 S. Employer dification No.)

(Zip Code)

8840 Wilshire Blvd., 2nd Floor, Beverly Hills, CA 90211

(Address of principal executive offices)

Edgar Filing: CAPRICOR THERAPEUTICS, INC. - Form 8-K

(310) 358-3200
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
the registrative and of the residentials.
"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CAPRICOR THERAPEUTICS, INC. - Form 8-K

Item 8.01 Other Events

Preliminary Clinical Data

On July 16, 2014 Capricor Therapeutics, Inc. (the "Company") issued a press release announcing completion of the analysis on the six-month MRI data of Phase I of the ALLSTAR clinical trial. This press release detailed preliminary efficacy data from the study which administered CAP-1002 in fourteen treated patients. Phase I of the ALLSTAR trial was funded in part by a grant received from the National Institutes of Health. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated July 16, 2014, announcing six-month results from Phase I ALLSTAR Trial

Edgar Filing: CAPRICOR THERAPEUTICS, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CAPRICOR THERAPEUTICS, INC.

Date: July 28, 2014 By:/s/ Linda Marbán, Ph.D. Linda Marbán, Ph.D. Chief Executive Officer